Last edition
News about "Wockhardt"
EMA Grants Accelerated Assessment to WCK 5222 by Wockhardt
The European Medicines Agency (EMA) has granted Accelerated Assessment status to Wockhardt’s WCK 5222, a fixed-dose combination of zidebactam and cefepime, following a pre-submission meeting—potentially enabling a faster regulatory review of the novel antibiotic therapy.
Wockhardt | 02/01/2026 | By News Bureau
Senores Pharmaceuticals Inks SPA to Raise Stake in Havix
Senores Pharmaceuticals Ltd. (SPL) has entered into a Share Purchase Agreement (SPA) with a public shareholder of Havix Group Inc., doing business as Aavis Pharmaceuticals (Havix), to acquire 6,730 equity shares — representing 2.97 percent of Havix’s total paid-up share capital.
Wockhardt | 14/07/2025 | By Dineshwori | 275
Wockhardt Realigns US Operations to Focus on Innovative Portfolio, Exits Generic Pharma Segment
Wockhardt has announced a strategic realignment of its US operations, exiting the loss-making generics business to focus on its innovation-led priorities in novel antibiotics and biologics, marking a decisive shift toward building a differentiated, future-ready pharmaceutical enterprise.
Wockhardt | 11/07/2025 | By Mrinmoy Dey | 244
Wockhardt | 28/06/2022 | By Sudeep Soparkar | 627
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy